<SEC-DOCUMENT>0001178913-26-002124.txt : 20260415
<SEC-HEADER>0001178913-26-002124.hdr.sgml : 20260415
<ACCEPTANCE-DATETIME>20260415123755
ACCESSION NUMBER:		0001178913-26-002124
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260415
DATE AS OF CHANGE:		20260415

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90328
		FILM NUMBER:		26863359

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		NON US STATE TERRITORY:  	L3
		PROVINCE COUNTRY:   	L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		NON US STATE TERRITORY:  	L3
		PROVINCE COUNTRY:   	L3
		ZIP:			7403648

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arkin Moshe
		CENTRAL INDEX KEY:			0001321178
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		6 HACHOSHLIM ST.
		CITY:			HERZELIA
		PROVINCE COUNTRY:   	L3
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
<schemaVersion>X0202</schemaVersion>
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0001178913-18-000468</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001321178</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>7</amendmentNo>
<securitiesClassTitle>Ordinary Shares, par value NIS 1.0 per share</securitiesClassTitle>
<dateOfEvent>03/25/2026</dateOfEvent>
<previouslyFiledFlag>false</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001684693</issuerCIK>
<issuerCusips>
<issuerCusipNumber>M8694L137</issuerCusipNumber>
</issuerCusips>
<issuerName>Sol-Gel Technologies Ltd</issuerName>
<address>
<com:street1>7 Golda Meir St.</com:street1>
<com:street2>Weizmann Science Park</com:street2>
<com:city>Ness Tziona</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>7403648</com:zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Perry Wildes, Adv.</personName>
<personPhoneNum>972-3-607-4444</personPhoneNum>
<personAddress>
<com:street1>One Azrieli Center</com:street1>
<com:city>Tel Aviv</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>6701101</com:zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0001321178</reportingPersonCIK>
<reportingPersonName>Moshe Arkin</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>PF</fundType>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<soleVotingPower>143257</soleVotingPower>
<sharedVotingPower>1806856</sharedVotingPower>
<soleDispositivePower>143257</soleDispositivePower>
<sharedDispositivePower>1806856</sharedDispositivePower>
<aggregateAmountOwned>1950113</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>56.6</percentOfClass>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<commentContent>Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b).&#13;
&#13;
Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026.</commentContent>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonNoCIK>Y</reportingPersonNoCIK>
<reportingPersonName>M. Arkin Dermatology Ltd.</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>WC</fundType>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<sharedVotingPower>1806856</sharedVotingPower>
<sharedDispositivePower>1806856</sharedDispositivePower>
<aggregateAmountOwned>1806856</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>52.44</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<commentContent>Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b).&#13;
&#13;
Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the Securities and Exchange Commission ("SEC") on March 24, 2026.</commentContent>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Ordinary Shares, par value NIS 1.0 per share</securityTitle>
<issuerName>Sol-Gel Technologies Ltd</issuerName>
<issuerPrincipalAddress>
<com:street1>7 Golda Meir St.</com:street1>
<com:street2>Weizmann Science Park</com:street2>
<com:city>Ness Tziona</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>7403648</com:zipCode>
</issuerPrincipalAddress>
</item1>
<item3>
<fundsSource>This amendment to Schedule 13D is being filed solely to update the percentage holdings of the Reporting Persons following the closing of the Issuer's underwritten offering that closed on March 25, 2026.</fundsSource>
</item3>
<item5>
<percentageOfClassSecurities>Item 5 of Schedule 13D is hereby amended and restated as follows:&#13;
&#13;
(a) and (b)&#13;
&#13;
As of March 25, 2026, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares.  Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology.&#13;
 &#13;
As of March 25, 2026, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 143,257 Ordinary Shares, which represented beneficial ownership of approximately 4.41% of the Company's outstanding Ordinary Shares.  Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. &#13;
&#13;
In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 1,806,856 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares.  Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology.&#13;
&#13;
The total Ordinary Shares beneficially owned by Mr. Arkin as of March 25, 2026, is 1,950,112, which represented beneficial ownership of 56.60% of the Company's outstanding Ordinary Shares.</percentageOfClassSecurities>
<transactionDesc>Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares.</transactionDesc>
<listOfShareholders>No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5.&#13;
&#13;
Percentages set forth in this amended Schedule 13D were calculated based on 3,245,270 Ordinary Shares outstanding on March 25, 2026 as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026.</listOfShareholders>
</item5>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>Moshe Arkin</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Moshe Arkin</signature>
<title>Moshe Arkin</title>
<date>04/13/2026</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>M. Arkin Dermatology Ltd.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Moshe Arkin</signature>
<title>Moshe Arkin, Director</title>
<date>04/13/2026</date>
</signatureDetails>
</signaturePerson>
</signatureInfo>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
